tradingkey.logo
tradingkey.logo
Search

Tempest Therapeutics Inc

TPST
Add to Watchlist
1.115USD
+0.005+0.45%
Market hours ETQuotes delayed by 15 min
15.99MMarket Cap
0.03P/E TTM

TradingKey Stock Score of Tempest Therapeutics Inc

Currency: USD Updated: 2026-06-30

Key Insights

Tempest Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 218 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 11.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Tempest Therapeutics Inc's Score

Industry at a Glance

Industry Ranking
218 / 387
Overall Ranking
391 / 4569
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Tempest Therapeutics Inc Highlights

StrengthsRisks
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are Amezalpat and TPST-1495. Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha. The ongoing global randomized Phase Ib/II trial of Amezalpat combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, a pathway implicated in multiple cancers.
Overvalued
The company’s latest PE is 0.03, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 4.51M shares, increasing 44.27% quarter-over-quarter.

Analyst Rating

Based on 1 analysts
Buy
Current Rating
11.000
Target Price
+900.00%
Upside Space

FAQs

How does TradingKey generate the Stock Score of Tempest Therapeutics Inc?

The TradingKey Stock Score provides a comprehensive assessment of Tempest Therapeutics Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Tempest Therapeutics Inc’s performance and outlook.

How do we generate the financial health score of Tempest Therapeutics Inc?

To generate the financial health score of Tempest Therapeutics Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Tempest Therapeutics Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Tempest Therapeutics Inc.

How do we generate the company valuation score of Tempest Therapeutics Inc?

To generate the company valuation score of Tempest Therapeutics Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Tempest Therapeutics Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Tempest Therapeutics Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Tempest Therapeutics Inc.

How do we generate the earnings forecast score of Tempest Therapeutics Inc?

To calculate the earnings forecast score of Tempest Therapeutics Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Tempest Therapeutics Inc’s future.

How do we generate the price momentum score of Tempest Therapeutics Inc?

When generating the price momentum score for Tempest Therapeutics Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Tempest Therapeutics Inc’s prices. A higher score indicates a more stable short-term price trend for Tempest Therapeutics Inc.

How do we generate the institutional confidence score of Tempest Therapeutics Inc?

To generate the institutional confidence score of Tempest Therapeutics Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Tempest Therapeutics Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Tempest Therapeutics Inc.

How do we generate the risk management score of Tempest Therapeutics Inc?

To assess the risk management score of Tempest Therapeutics Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Tempest Therapeutics Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Tempest Therapeutics Inc.